

# Machine learning-assisted treatment selection for smoking cessation

Gaylen E Fronk<sup>aff-1</sup>, Kendra Wyant<sup>aff-1</sup>, Megan E Piper<sup>aff-2</sup>, Timothy Baker<sup>aff-2</sup>, and John J. Curtin<sup>aff-1</sup>

<sup>aff-1</sup>Department of Psychology, University of Wisconsin-Madison

<sup>aff-2</sup>Center for Tobacco Research & Intervention, University of Wisconsin-Madison

## Abstract

Precision mental health seeks to select the right treatment for a patient given personal characteristics. The purpose of this project was to build a machine learning model that could select among first-line medication treatments for cigarette smoking. We used data from a previously completed comparative effectiveness trial in which participants were richly characterized at baseline before being randomly assigned to varenicline, combination nicotine replacement therapy, or nicotine patch. We built a model predicting treatment success (abstinent vs. smoking) using baseline characteristics and their interactions with treatment. Models were fit, selected, and evaluated using nested cross-validation and the performance metric area under the receiving operator characteristic curve (auROC). Our best models had a median auROC of 0.69 in held-out test sets. We used this model to calculate probabilities of treatment success for each participant on each of the three treatments to identify their model-predicted best treatment. Individuals who were matched to their model-predicted best treatment during the original trial were more likely to quit successfully at 4 weeks than individuals who were not (OR = 1.382,  $p = 0.014$ ) but not at later timepoints. This project produces a clinically implementable treatment selection model to assist people quitting cigarette smoking.

*Keywords:* Substance use disorders Precision mental health Cigarette smoking- Machine learning Treatment selection

## Introduction

Precision medicine seeks to guide and personalize treatment selection using individual difference characteristics that are likely to predict treatment success for each patient (Bickman, 2020). Successful precision medicine would increase the likelihood of treatment success for each patient and improve treatment effectiveness rates across the population.

Precision mental health is the application of the precision medicine paradigm to mental health conditions (Bickman, 2020; Bickman et al., 2016; DeRubeis, 2019; Insel, 2014). Treatments for mental health conditions are usually no more than moderately effective, and many treatments for the same disorder can be quite comparable (Adjei & Ali, 2022; Lewis et al., 2020; Weisz et al., 2019). Precision mental health models may allow us to select among these treatments to improve

mental healthcare. Consequently, many researchers have pursued precision mental health in recent years (DeRubeis, 2019).

Despite the abundance of research, much less progress has been made to personalize treatments for mental health disorders compared to treatments for medical disorders (Bickman, 2020; Bickman et al., 2016; Kessler & Luedtke, 2021; Kranzler et al., 2017; Oliver & McClernon, 2017). One possible reason for this is that many factors influence heterogeneous, complex clinical phenomena like mental health diagnoses and treatment success (Feczko & Fair, 2020). Thus, any single feature (i.e., predictor variable) cannot account for more than a small portion of the variance in treatment success (Insel, 2014; Kessler & Luedtke, 2021). Precision mental health efforts so far, however, have largely focused on personalizing treatments using only a single feature (DeRubeis, 2019). It is perhaps unsurprising that models that consider only one or a small handful of features - which also limits considering features from different categories concurrently - have failed to capture the real-world complexity underlying clinical phenomena like treatment success.

Additionally, because models are typically developed and evaluated in the same sample, the models may become very overfit to that sample (Jonathan et al., 2000). This problem is exacerbated in precision mental health because sample sizes in psychological research have remained relatively small despite recommendations to increase sample size (Marszalek et al., 2011). Consequently, precision mental health models do not generalize well to new patients.

To capture sufficient complexity to predict treatment success, we need to increase the total number of features in precision mental health models. Incorporating more features, however, makes overfitting the data more likely. Thus, successful precision mental health requires an analytic approach that can handle high-dimensional data without becoming too overfit to generalize to new patients.

### **Applying machine learning approaches**

Machine learning may be able to advance precision mental health goals (Bickman et al., 2016; Dwyer et al., 2018; MacEachern & Forkert, 2021; Mooney & Pejaver, 2018). These models use statistical algorithms trained on high-dimensional arrays (hundreds or even thousands) of features (James et al., 2013; Kuhn & Johnson, 2018; Ng, 2018). Machine learning uses various techniques (e.g., regularization, hyperparameter tuning, simultaneous consideration of many model configurations) within resampling methods such as cross-validation to accommodate high-dimensional sets of features while reducing overfitting (James et al., 2013; Jonathan et al., 2000; Krstajic et al., 2014; Kuhn & Johnson, 2018; Mooney & Pejaver, 2018; Ng, 2018). Thus, we can build precision mental health models that capture complex clinical phenomena and generalize accurately to new data.

### **Cigarette smoking as a critical precision mental health target**

Combining precision mental health and machine learning may be able to improve treatment for cigarette smoking. Smoking remains an enormous public health burden. Tobacco is the leading cause of preventable death in the U.S., accounting for more than 480,000 deaths annually (Cornelius, 2020; National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health, 2014; Schlam & Baker, 2013). Individuals who smoke have two- to three-fold likelihood of death across causes and lose over a decade of life expectancy (Jha Prabhat et al., 2013).

Although rates of smoking have declined considerably, approximately 14% of U.S. adults continue to smoke daily or near-daily (Cornelius, 2020; Substance Abuse and Mental Health Services Administration, 2023). Additionally, cigarette smoking rates remain much higher in potentially vulnerable populations. This includes people with chronic or severe mental illness including

other substance use disorders; Native American and non-Hispanic Black individuals; individuals who are economically and educationally disadvantaged; people in the criminal legal system; people experiencing homelessness; individuals who are uninsured or insured through Medicaid; and people who identify as lesbian, gay, or bisexual (Baggett et al., 2013; Baker & McCarthy, 2021; Cornelius, 2020; Cropsey et al., 2004; Harrison et al., 2020; Jamal et al., 2015; Kelly et al., 2012; Soar et al., 2020).

The best available smoking cessation treatments are modestly effective. The medications varenicline and combination nicotine replacement therapy (C-NRT) are the most effective options when combined with psychosocial counseling, yielding 6-month treatment success rates of 30-35% (Baker & McCarthy, 2021; Cahill et al., 2013; Fiore et al., 2008; Rigotti et al., 2022; Schlam & Baker, 2013). Varenicline and C-NRT appear to be equally effective (Baker et al., 2016; Cahill et al., 2013). Indeed, national clinical guidelines note that “there are no well-accepted algorithms to guide optimal selection” between any of the first-line medications ((Fiore et al., 2008), p. 44). These facts suggest a critical need for precision mental health approaches in the cigarette smoking domain.

### ***Previous research***

To select among treatments for smoking cessation, precision mental health models must be built using *many features* and *multiple treatments*. Using a high-dimensional array of features is necessary to predict a complex clinical outcome like treatment success. Including multiple treatments allows for interactions among treatments and features that are needed to make differential predictions by treatment.

There is a large body of research identifying features that predict overall treatment success (i.e., irrespective of treatment) (Etter et al., 2023; Issabakhsh et al., 2023; Kaufmann et al., 2015; Kaye et al., 2020; Lai et al., 2021; Megan E. Piper, Schlam, et al., 2017) or treatment success when using a single treatment (Coughlin et al., 2020; Massago et al., 2024). However, these models that do not include multiple treatments do not offer an actionable way forward to select among treatment options. Even research that informs us as to who might succeed within a specific treatment has limited utility for treatment selection: what do we do for a patient who is not predicted to succeed using that treatment?

Some research has begun to build models that consider multiple treatments simultaneously (Chen et al., 2020; Chenoweth et al., 2016; Glatard et al., 2017; Kaye et al., 2020; Lerman et al., 2015; Piper et al., 2016; Megan E. Piper, Cook, et al., 2017; Megan E. Piper, Schlam, et al., 2017; Schnoll et al., 2009; Shahab et al., 2019; Siegel et al., 2020). However, each study examined only a single feature or examined each feature in a separate model, which cannot explain sufficient variance in complex clinical outcomes.

### ***Opportunities for treatment selection***

Although there is not yet much research selecting among smoking cessation treatments, there may be reason to expect that some treatments may work better than others for a specific individual. First, there is enormous heterogeneity among people who smoke cigarettes (Oliver & McClernon, 2017; Wang et al., 2009; Zheng et al., 2013). Second, smoking cessation medications have distinct pharmacological mechanisms of action that may affect how helpful they are for different people (Cahill et al., 2016; Jordan & Xi, 2018; Lieberman, 2004). Third, the many behavioral and environmental features that have been shown to predict overall treatment success may also guide treatment selection, alone or in combination with medication mechanisms of action (Bickel et al., 2023). Finally, there is some evidence of differential effectiveness, adherence, and preference for

treatments across individuals (Cropsey et al., 2017; Fiore et al., 2008; Gonzales et al., 2014; Heckman et al., 2017; Lindson et al., 2019; Tønnesen et al., 1993).

## Purpose

The goal of this project was to produce and evaluate a treatment selection model to select among medications for smoking cessation. We used data from a previously completed comparative effectiveness trial of varenicline, C-NRT, and nicotine patch (Baker et al., 2016). We built a model to predict treatment success using a high-dimensional array of baseline individual difference features and three smoking cessation treatments. We evaluated the clinical benefit of this treatment selection model to determine whether using our model to select treatments can increase abstinence following quitting smoking.

## Methods

### Transparency & openness

We adhere to research transparency principles that are crucial for robust and replicable science. We reported how we determined the sample size, all data exclusions, all manipulations, and all study measures. We provide a transparency report in the supplement . Finally, our data and other study materials are publicly available on our OSF page, and our annotated analysis scripts and results are publicly available on our study website.

### Data

The data for this project came from a completed randomized controlled trial conducted by the University of Wisconsin (UW) Center for Tobacco Research and Intervention (CTRI) (Baker et al., 2016). This trial compared the effectiveness of three cigarette smoking cessation treatments (varenicline, combination nicotine replacement therapy [C-NRT], and nicotine patch). Briefly, 1086 adults who smoked cigarettes daily and were looking to quit smoking were enrolled in Madison, WI, USA and Milwaukee, WI, USA. Smoking was biochemically verified. Participants were smoking approximately 17 cigarettes per day ( $M = 17.03$ ,  $SD = 8.31$ ) at study enrollment. Exclusion criteria included contraindicated medical (e.g., severe hypertension) or psychiatric (e.g., severe and persistent mental illness) conditions; current use of contraindicated medications; and pregnancy or unwillingness to use appropriate methods of contraception while taking a study medication. Participants set a quit date with study staff and were enrolled for several weeks prior to the target quit date through at least 6 months following quitting smoking.

### *Treatment conditions*

Participants were randomly assigned to one of three medication conditions: varenicline, C-NRT, or nicotine patch. For varenicline, participants began medication use prior to their quit attempt, starting with 0.5 mg once daily for 3 days, followed by 0.5 mg twice daily for 4 days. On the target quit date, participants increased to 1 mg twice daily and continued this dose for 12 weeks except in response to adverse events. For C-NRT or nicotine patch, participants initiated treatment on their quit date. Patch dosing was 8 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg. All individuals who received C-NRT were also instructed to use at least 5 lozenges per day (2 or 4 mg nicotine lozenges determined by time to first daily cigarette) for the full 12 weeks except in the case of adverse effects.

All participants also received counseling per clinical guidelines (Fiore et al., 2008). Participants received 5 in-person counseling sessions (pre-quit, quit day, week 1, week 4, week 12) and 1

phone counseling session (week 8). Counseling consisted of motivational interviewing/enhancement techniques, supportive therapy, and skill training elements.

### *Individual difference characteristics*

Participants were comprehensively assessed for individual difference characteristics prior to treatment randomization. These characteristics fall into several domains expected to relate to cigarette smoking cessation: tobacco-related (e.g., cigarettes per day), psychological (e.g., psychiatric diagnoses, distress tolerance), physical health (e.g., vital signs), social/environmental (e.g., living with another person who smokes), and demographic (e.g., age, sex). A detailed list of all available individual differences variables appears in Table 1.

Table 1: Individual Differences Characteristics Available for Model Features

Demographic Characteristics	Feature Name	Type	# Items
	Gender	Categorical (unordered)	1
	Age	Numeric	1
	Race	Categorical (unordered)	1
	Marital Status	Categorical (unordered)	1
	Income	Categorical (ordered)	1
	Ethnicity	Categorical (unordered)	1
	Employment	Categorical (unordered)	1

Table 1: Individual Differences (Continued)

Smoking Use/History	Feature Name	Type	# Items
	Baseline Carbon Monoxide	Numeric	1
	Carbon Monoxide Exposure	Categorical (unordered)	1
	Age of 1st Cigarette	Numeric	1
	Age Became Daily Smoker	Numeric	1
	Years Smoking	Numeric	1
	Cigarettes Per Day (Heaviest)	Numeric	1
	Use of Other Tobacco Products	Categorical (unordered)	5
	Number of Previous Quit Attempts	Numeric	1
	Last Recent Quit Attempt	Categorical (ordered)	1
	Longest Quit Attempt	Categorical (ordered)	1
	Previous Quit Methods Used	Categorical (unordered)	6
	Cigarettes Per Day (Current)	Numeric	1
	Motivation to Quit	Categorical (ordered)	1
	Self-Efficacy for Quitting in Next 30 Days	Categorical (ordered)	1
	Confidence to Quit	Categorical (ordered)	1
	Importance to Quit	Categorical (ordered)	1
	DSM5 Tobacco Use Disorder (American Psychiatric Association, 2013)	Categorical (unordered)	13
	Fagerstrom Test of Nicotine Dependence (Heatherton et al., 1991)	Categorical (unordered); Categorical (ordered)	6
	Wisconsin Inventory of Smoking Dependence Motives-37 (Smith et al., 2010)	Categorical (ordered)	37
	Smoke Menthol Cigarettes	Categorical (unordered)	1
	Wisconsin Smoking Withdrawal Scale-2 (Smith et al., 2021)	Categorical (ordered)	38

Table 1: Individual Differences (Continued)

Social & Environmental Characteristics	Feature Name	Type	# Items
	Spouse Smokes	Categorical (unordered)	1
	Live with Another Smoker	Categorical (unordered)	1
	People Close to You Who Smoke	Categorical (unordered)	5
	Ban on Smoking at Home	Categorical (unordered)	1
	Ban on Smoking at Work	Categorical (unordered)	1
	Time Around Other Smokers	Categorical (ordered)	2

Mental Health & Psychological Traits	Feature Name	Type	# Items
	Frequency of Drinking Alcohol	Categorical (ordered)	1
	Quantity of Alcohol	Categorical (ordered)	1
	Binge Drinking	Categorical (ordered)	1
	Short Inventory of Problems-2 (Revised) (Kiluk et al., 2013)	Categorical (ordered)	15
	Life Satisfaction	Categorical (ordered)	1
	Life Enjoyment	Categorical (ordered)	1
	Psychological Disorder Diagnoses	Categorical (unordered)	7
	Positive and Negative Affect Schedule (Crawford & Henry, 2004)	Categorical (ordered)	6
	Snaith-Hamilton Pleasure Scale (Snaith et al., 1995)	Categorical (ordered)	14
	Anxiety Sensitivity Index-3 (Taylor et al., 2007)	Categorical (ordered)	18
	Distress Tolerance Scale (Simons & Gaher, 2005)	Categorical (ordered)	15
	Patient History Questionnaire-9 (Kroenke et al., 2001)	Categorical (ordered)	9

Table 1: Individual Differences (Continued)

Medical & Physical Health	Feature Name	Type	# Items
	Diabetes Diagnosis	Categorical (unordered)	1
	Multidimensional Fatigue Inventory (Smets et al., 1995)	Categorical (ordered)	20
	Berlin Sleep Questionnaire (Netzer et al., 1999)	Categorical (ordered), Categorical (unordered)	3
	Body Mass Index	Numeric	1
	Health-related Quality of Life Scale (Taylor & National Center for Chronic Disease Prevention and Health Promotion (U.S.). Division of Adult and Community Health, 2000)	Categorical (ordered), Nu- meric	4
	Healthy Days Symptoms Module (Moriarty, 1996)	Numeric	5

Miscellaneous Features	Feature Name	Type	# Items
	Treatment	Categorical (unordered)	1
	Incarcerated	Categorical (unordered)	1
	Works Third Shift	Categorical (unordered)	1

### *Treatment success outcome*

Throughout study participation, treatment success was assessed via biologically confirmed, 7-day point-prevalence abstinence. Point-prevalence abstinence assesses for any smoking (here, in the previous 7 days) and yields a single, dichotomous outcome of “abstinent” or “smoking.” Participants self-reported whether they had smoked over the past 7 days, and their report was biologically confirmed via exhaled carbon monoxide (CO). Participants were labeled as “abstinent” if their CO level was less than 6 parts per million (ppm; (Baker et al., 2016)). If participants self-reported any smoking in the past 7 days, their CO level contradicted their self-report (i.e., CO level > 6 ppm), or biological confirmation could not be confirmed, participants were labeled as “smoking.”

Assessments of treatment success were used in two separate ways. During model building, treatment success at 4 weeks post-quit served as the *prediction outcome for our models* (i.e., predicting if individuals were labeled “abstinent” or “smoking” at 4 weeks). We selected treatment success at 4 weeks in order to 1) predict an outcome that would allow individuals to pivot to a different medication earlier if their treatment was unsuccessful; and 2) evaluate the differential effects of treatment while participants were actively using the medications.<sup>1</sup>

<sup>1</sup>We fit additional models predicting treatment success at 12 and 26 weeks, and these models had significantly worse performance than our 4 week prediction model, supporting our choice to use the 4 week model (See Supplement).



Treatment success also served as the outcome for *clinical benefit analyses*. We evaluated whether using our treatment selection model yielded higher treatment success (i.e., higher rates of abstinence) at 4, 12, and 26 weeks post-quit.

## Model building

Data preprocessing, modeling, and Bayesian analyses were done in R using the tidymodels ecosystem (Kuhn & Wickham, 2020). Models were trained and evaluated using high-throughput computing resources provided by the University of Wisconsin Center for High Throughput Computing (Center for High Throughput Computing, 2006). Additional details about model building and evaluation appear in the Supplement.

### Feature engineering

We followed standard practices for generic feature engineering steps (see Supplement). Treatment was one-hot-coded such that there were three features, one corresponding to each treatment (varenicline, C-NRT, nicotine patch). The three treatment features were allowed to interact with all other features to permit differential prediction. A sample feature engineering script (i.e., tidymodels recipe) containing all feature engineering steps is available on our OSF study page (<https://osf.io/qad4n/>).

### Model configurations

All model configurations used the statistical algorithm Elastic Net Logistic Regression (GLMNet) and differed across sensible values for the associated hyperparameters, alpha and lambda. This algorithm aligned with our application goals: GLMNet allows including interaction terms explicitly (i.e., interactions between treatment and all other features), and it reduces dimensionality by penalizing model complexity. Model configurations differed by 1) whether feature sets included individual items within a self-report measure or total scale/sub-scale scores derived from items, and 2) whether ordered categorical data (e.g., Likert scale items) were ordinal scored or one-hot coded.

### Model selection & evaluation

We used nested  $k$ -fold cross-validation for model training, selection, and evaluation (Krstajic et al., 2014). Nested cross-validation uses two nested loops for dividing and holding out folds: an outer loop, where held-out folds serve as *test sets* for model evaluation; and inner loops, where held-out folds serve as *validation sets* for model selection. We used 1 repeat of 10-fold cross-validation (i.e.,  $k = 10$ ) for the inner loops and 3 repeats of 10-fold cross-validation for the outer loop.

Models were selected and evaluated using auROC, which indexes the probability that the model will predict a higher score for a randomly selected positive case (abstinent) relative to a randomly selected negative case (smoking) (Kuhn & Johnson, 2018; Youngstrom, 2014). Because it was important that our model retained interaction features, we defined a “satisficing metric” of 50 or more treatment interaction features retained (Ng, 2018). Best model configurations were selected using median auROC among model configurations that retained a median of 50 treatment interaction features across the 10 *validation sets*. Final performance evaluation of those best model configurations used median auROC across the 30 *test sets*.

We used a Bayesian hierarchical generalized linear model to estimate the posterior probability distributions and 95% Bayesian credible intervals (CIs) for test set auROC. We estimated the posterior probability distribution around model performance following recommendations from the tidymodels team (Kuhn, 2022). The median posterior probability for auROC represents our best estimate for the magnitude of the auROC parameter for each model. If the credible intervals do not contain .5 (chance performance), this suggests our model is capturing signal in the data.

## Model interpretation

Interpretability is important when using machine learning for clinical applications to identify important features and encourage implementation (Cohen & DeRubeis, 2018; MacEachern & Forkert, 2021; Mooney & Pejaver, 2018). We reviewed the retained features and their parameter estimates as a metric of feature importance because GLMNet only retains features whose contribution outweighs the additional complexity.

We also computed Shapley Values (Lundberg & Lee, 2017) to provide a consistent, objective explanation of feature importance. We calculated Shapley values using leave-one-out  $k$ -fold cross-validation (LOOCV), where the value of  $k$  is set to  $N$  (sample size) such that each test set consists of a single held-out participant. Shapley values were calculated for each held-out participant using a model fit with the other 1085 participants and the final, best selected model configuration.

We used the DALEX and DALEXtra packages (Biecek, 2018) in R, which provide local Shapley values (i.e., for each observation) in log-odds units for binary classification models. To index global feature importance, we averaged the absolute value of the local Shapley values of each feature across observations. Shapley values are additive, which allowed us to create two feature categories, Main Effects and Interactions. We calculated global importance of each feature category by averaging the absolute value of the Shapley values of all features in the category across observations. These global importance scores allowed us to contextualize relative feature importance for each feature and feature category.

## Clinical benefit evaluation

### *Select final model configuration*

To get a single, final model, we replicated our inner loop resampling (1 repeat of 10-fold cross-validation) on the full dataset. The best model configuration was selected using median auROC across the 10 held-out folds (among model configurations that retained a median of 50 treatment interaction features). A final model was fit on the full dataset using this best selected model configuration to obtain parameter estimates for interpretation.

### *Identify model-predicted best treatment*

We made predictions for each held-out participant using LOOCV (i.e., model is fit with the other 1085 participants). This approach matches real-world implementation in that we are making predictions for a new patient the model has not seen. We calculated three predicted probabilities for each participant by substituting each treatment into the model inputs. This produced one prediction per person per treatment. The treatment that yielded the highest model-predicted probability of abstinence was identified as that participant’s “best” treatment.

For example, an individual received varenicline in the original trial. We calculated their probability of abstinence using their data (i.e., with varenicline as the “treatment” feature), and we calculated two additional probabilities by substituting C-NRT and nicotine patch for varenicline. Their probability of abstinence was highest when substituting C-NRT, meaning C-NRT was identified as their best treatment.

### *Categorize treatment matching*

Some participants’ best treatment matched what they were randomly assigned in the original trial. Other participants may have received a sub-optimal treatment (i.e., what the model identified as their second-best or worst treatment based on calculated probabilities). Thus, participants could be categorized by whether they received their best treatment or another treatment in the original trial.

For example, the individual described above received varenicline in the original trial, but their model-predicted probability of abstinence was highest when substituting C-NRT for treatment. This participant’s best treatment did not match their trial treatment, so they were labeled as matched to “other treatment.”

### ***Evaluate clinical benefit***

Our primary analysis evaluated the clinical benefit of our treatment selection model by comparing the observed outcomes (i.e., abstinence vs. smoking from the original trial) for people who were matched to their best treatment or to another treatment (between-subjects; 0.5 [“best treatment”] vs.  $-0.5$  [“other treatment”]).

We examined this effect over time at 4, 12, and 26 weeks. Calculating and interpreting interactions in logistic models is not straightforward because significance can differ based on the link function used (Collins, 2018; Karaca-Mandic et al., 2012). Consequently, we conducted three, separate generalized logistic regression models where we regressed the outcome (abstinent vs. smoking) on treatment matching. We conducted these regressions using the lme4 package in R (Bates et al., 2015). We also conducted sensitivity analyses using only participants who reported starting their medication (i.e., any medication use reported during the first 4 weeks post-quit;  $N = 988$ ).

### **Fairness benchmarks**

We aim for the responsible and transparent reporting of model performance and clinical utility, and we acknowledge that models that work for only a subset of people, if implemented, could widen existing treatment disparities. Consequently, we conducted fairness analyses on our model performance (i.e., auROC) and clinical benefit. We conducted analyses separately for three dichotomized demographic groups that display higher rates of cigarette smoking and/or encounter additional barriers to receiving treatment for substance use disorders: 1) race and ethnicity (non-Hispanic White vs. non-White); 2) income (above vs. below poverty line); and 3) sex at birth (male vs. female) (Cornelius, 2020; Jamal et al., 2015; Kilaru et al., 2020; Olfson et al., 2022; Pinedo, 2019)

For fairness of model performance, we conducted Bayesian model comparisons to assess the likelihood that the model performs differently by demographic group. We report median differences in posterior probabilities and the 95% Bayesian CIs around these differences. For fairness of clinical benefit, we compared the benefit of treatment selection (i.e., matched to best treatment vs. other treatment) at each time (4 weeks, 12 weeks, 26 weeks) by demographic group. We report the parameter estimate, confidence interval, and  $p$ -value for the effect of demographic group in each model.

## **Results**

### **Sample characteristics**

All 1086 participants who were randomized to treatment in the comparative effectiveness trial (Baker et al., 2016) were included in our analysis sample. Demographic characteristics of this sample appear in Table 2. Smoking-related characteristics of this sample appear in Table 3.

Table 2: Demographic Characteristics

Characteristic	N (%)	Mean (SD)
Age		48.13 (11.6)
Gender		
Female	566 (52.12%)	
Male	520 (47.88%)	
Race		
Asian	3 (0.28%)	
Black/African American	309 (28.45%)	
Multiracial	22 (2.03%)	
Native American/Alaska Native	6 (0.55%)	
Other	18 (1.66%)	
White	728 (67.03%)	
Ethnicity		
Hispanic or Latino/a	27 (2.49%)	
Non-Hispanic	1059 (97.51%)	
Marital Status		
Divorced	224 (20.63%)	
Living with a domestic partner	87 (8.01%)	
Married	384 (35.36%)	
Never married	299 (27.53%)	
Separated	53 (4.88%)	
Widowed	34 (3.13%)	
Did not respond	5 (0.46%)	
Employment		
Employed (full-time)	474 (43.65%)	
Employed (part-time)	283 (26.06%)	
Unemployed	329 (30.29%)	

Table 2: Demographic Characteristics (Continued)

Characteristic	N (%)	Mean (SD)
Income		
< \$10,000	210 (19.34%)	
\$10,000 - \$19,999	135 (12.43%)	
\$20,000 - \$24,999	83 (7.64%)	
\$25,000 - \$34,999	129 (11.88%)	
\$35,000 - \$49,999	149 (13.72%)	
\$50,000 - \$74,999	160 (14.73%)	
\$75,000+	167 (15.38%)	
Did not respond	53 (4.88%)	

Table 3: Smoking Use &amp; History Characteristics

Characteristic	Mean (SD)	N (%)
Age of first cigarette	14.6 (3.42)	
Age became daily smoker	17.56 (4.62)	
Years smoking	28.65 (12.03)	
Cigarettes per day (heaviest)	22.74 (10.67)	
Number of previous quit attempts	3.91 (6.03)	
Cigarettes per day (current)	17.03 (8.31)	
Number of DSM5 tobacco use disorder symptoms	4.57 (2.17)	
WISDM37 Total Score	3.99 (1.17)	
WSWS Total Score	48.82 (19.91)	
Time to first cigarette upon waking		
After 60 minutes		82 (7.55%)
31 - 60 minutes		157 (14.46%)
6 - 30 minutes		477 (43.92%)
Within 5 minutes		366 (33.7%)
Did not respond		4 (0.37%)

### Model performance

The median auROC across the 30 test sets for the 4-week model was 0.695 (IQR = 0.667 - 0.718, range = 0.592 - 0.788). Figure 1, Panel A shows the ROC curve for held-out test set performance (concatenated across 30 held-out folds).




Figure 1: Model performance for prediction model. A) ROC curve plotted across all values of sensitivity (true positive rate) and specificity (1 - false positive rate). Dotted line indicates chance performance. B) Posterior probability distribution for the median auROC in test sets. Histogram represents posterior probability distribution. Horizontal line displays 95% Bayesian credible interval. C) Model calibration between predicted probabilities and observed values. Predicted probabil-

We used the 30 test set auROCs to estimate the posterior probability distribution for the auROC of these models. The median auROC from the posterior distribution was 0.693. This value represents our best estimate for the magnitude of the auROC parameter. The 95% Bayesian CI for the auROC was relatively narrow [0.674 - 0.711] and did not contain 0.5 (chance performance), suggesting this model has predictive signal. Figure 1, Panel B displays the posterior probability distribution for the auROC.

In Figure 1, panel C, we display our model’s calibration. This figure plots the predicted probabilities for each individual for their original trial-assigned treatment against the observed trial treatment success. Predicted probabilities are binned (bin width = 10%) and plotted against the observed probability of abstinence for observations in that bin. If probabilities were perfectly calibrated, all bin means would fall on the dotted line (e.g., bin from 0 - 10 with an observed mean probability of 0.05, bin from 10 - 20 with an observed mean probability of 0.15). Probabilities are well calibrated and ordinal in their relationship with the true probability of abstinence.


### Model interpretation

Our final model fit with the full dataset retained 155 features overall including 74 treatment interactions (see Supplemental Table X for retained feature list). To perform treatment selection, only interactive features need to be assessed, as features that increase or decrease probabilities equally across treatments do not help with differential prediction. Implementing this model for treatment selection requires assessing only 52 unique items (e.g., multiple dummy variables are from a single item, the same feature interacts with more than one treatment).

Global feature importance (mean |Shapley value|) from our model appears in Figure 2. Shapley values describe the relative importance of these individual features for making predictions. Six of the top 25 most globally important features were treatment interactions. UPDATE FIGURE TO ONLY BE PANEL A

## Top Global Shapley Values

A



B




Figure 2: Global feature importance via Shapley values. Bar represents magnitude of global feature importance, which is calculated from the mean of the absolute value across all observations for that feature. A) Global feature importance for top 25 features overall. B) Global feature importance for top 25 treatment interaction features.



### Clinical benefit

There was a significant fixed effect of treatment matching on abstinence at 4 weeks ( $OR = 1.382$ ,  $z = 2.452$ ,  $p = 0.014$ ) such that individuals who received their model-predicted best treatment were more likely to be abstinent. The effect of treatment matching was no longer significant at 12 weeks ( $p = 0.232$ ) or at the 26-week follow-up assessment ( $p = 0.943$ ). Figure 3 shows the mean abstinence rate by treatment matching at each time point. The pattern of results was identical when including only individuals who reported any medication use in the analysis sample.




Figure 3: Benefit of treatment matching. Bars represent mean observed abstinence (from original trial) for individuals who did and did not receive their model-predicted best treatment, over time. Error bars indicate standard errors.

### Fairness benchmarks

Model performance was better for male (vs. female) participants (median increase in  $auROC = 0.056$  [95% CI 0.026 - 0.087]). Unexpectedly, model performance was better for non-White (vs. non-Hispanic White) participants (median increase in  $auROC = 0.048$  [95% CI 0.013 - 0.084]) and for participants below (vs. above) the national poverty line (median increase in  $auROC = 0.033$  [95% CI 0.004 - 0.062]).<sup>2</sup>

Clinical benefit fairness analysis results here!

<sup>2</sup>Fifty-three participants (4.9%) did not provide income data and were excluded from this analysis.

## Discussion

In this project, we produced a treatment selection model that can offer immediate benefit to individuals looking to quit smoking using several first-line medications. Individuals who received their model-predicted best treatment in the original trial had a mean abstinence rate that was 7.4% higher than individuals who did not (38.9% vs. 31.5%) at 4 weeks. Although this absolute difference may seem somewhat small, this corresponds to a 23.5% *relative* improvement - simply by allocating treatments to the right person.

We feel confident in this effect for several reasons. First, we made predictions for each individual to identify their best treatment while they were held-out from model fitting to match how this model will be used in clinical practice (i.e., to make predictions and select a treatment for new patients). Second, our model is capturing predictive signal, as supported by the Bayesian CI around our model’s auROC, adding to our trust in the model’s prediction outputs. Third, these predictions were well-calibrated such that we can trust their ordinal ranking. This is critical because what is used in our treatment selection process is the relative *order* (i.e., rank) of predicted probabilities for each person rather than the values themselves.

We can achieve this benefit using an accessible, low-burden assessment. Implementing this treatment selection model would require assessing approximately 50 multiple choice and yes/no questions, which survey research suggests would take 11-12 minutes to complete (Lenzner et al., 2010). Additionally, because all items are self-report questions, this assessment can be completed remotely (e.g., administered online) and can be made available to people without access to in-person medical care. This assessment tool is particularly valuable in this context because two treatments in the model (C-NRT, nicotine patch) are widely available over-the-counter, offering scalable implementation when healthcare access is limited.

This focus on accessibility is especially important given disparities in mental healthcare. Access to treatment is a known barrier in mental healthcare and a contributing factor driving healthcare disparities (Jacobson et al., 2022). Cigarette smoking rates remain higher in many marginalized populations (Baggett et al., 2013; Baker & McCarthy, 2021; Cornelius, 2020; Cropsey et al., 2004; Harrison et al., 2020; Jamal et al., 2015; Kelly et al., 2012; Soar et al., 2020). Prioritizing accessibility in implementation is a critical first step towards mitigating rather than exacerbating health disparities (MacEachern & Forkert, 2021).

We aimed to further address this goal with our fairness benchmark analyses. We found that our prediction model performed worse for females than men; however, it performed better for non-White individuals and individuals below the poverty line. (CLINICAL BENEFIT RESULTS DISCUSSION HERE - MAY NEED TO ADJUST CONCLUSIONS). These findings suggest our model may be well-positioned to improve treatment equity. If our goal is to reduce and ultimately close the treatment gap between privileged individuals and individuals often disadvantaged in research efforts and mental healthcare, then we need tools such as this model that offer *additional* benefit to those disadvantaged demographic groups.

## Long-term outcomes

### *Challenges of predicting distal treatment success*

Alongside these exciting findings, this study also demonstrates that it is difficult to predict complex outcomes like treatment success using distal predictors. Our best estimate of median auROC in held-out data (from the posterior probability distribution) was 0.69, indicating that our model correctly assigns a higher probability to a positive (abstinent) case than a negative (smoking) case 69% of the time. An auROC of 0.7 to 0.8 is considered “acceptable” (Mandrekar, 2010). Our model

was right on the cusp of this range. Nevertheless, there is room for improvement in our model’s predictive performance.

It is important to note, however, that our primary goal was *not* overall prediction of treatment success. Capturing some signal with our model was necessary to yield credible predictions and establish the relevance of features, and so our model’s modest predictive performance may have impacted our ability to select treatments. However, overall prediction was insufficient for our purpose. A model that predicted treatment success perfectly (i.e., auROC of 1.0) but included no interactions would be useless for treatment selection. Indeed, this fact motivated our use of a satisficing metric for a minimum number of interaction terms retained in our models, even though it is possible that we sacrificed some level of predictive power by imposing that additional criterion.

### ***Improving long-term benefit of treatment selection***

The clinical benefit that our treatment selection model offers is short-lived. There is no longer statistically significant benefit of treatment matching at 12 weeks, though there is a numeric difference (31.2% abstinence vs. 27.8% abstinence), and there is no statistical or numeric difference at all by 6 months.

Initial treatment success is critical, especially for cigarette smoking where even reducing smoking or quitting for a short period of time can improve health outcomes and life expectancy (Jha Prabhat et al., 2013). Additionally, smoking early in a quit attempt can have strong negative consequences: decreased self-efficacy, reduced treatment adherence, and premature treatment cessation (Schlam & Baker, 2013). Findings such as these highlight that selecting a treatment that increases treatment success in early recovery (i.e., at 4 weeks) is necessary - though not sufficient - for long-term success.

Nevertheless, we were of course hopeful that treatment matching benefits would endure. However, it is perhaps unsurprising that they do not. There may be several possibilities for the lack of benefit at later assessment points.

First, it is possible that we could have improved prediction overall and treatment selection if we incorporated biological markers or genetic features (Chen et al., 2018). However, extant literature has primarily used single candidate genes or biomarkers, has also not found long-term benefits, and has not translated well into real-world settings (Chen et al., 2020; Chenoweth et al., 2016; Glatard et al., 2017; Lerman et al., 2015; Schnoll et al., 2009; Shahab et al., 2019; Siegel et al., 2020). Additionally, the potential improvement that could come from including biological or genetic features carries an associated cost to implementation given the relative inaccessibility of genetic and biological testing (MacEachern & Forkert, 2021).

A second possibility is that we failed to include non-biological/non-genetic features that are critical for predicting treatment success later on. However, our data come from a large comparative effectiveness trial conducted by a nationally recognized center and designed by foremost experts in the field (Baker et al., 2016). The baseline assessment was quite comprehensive and was based on domain expertise and decades of research. Thus, it seems unlikely that we could be missing enough important features to bridge the gap in our benefit of treatment selection.

We believe the most likely possibility is that our model did not capture dynamic changes over time. It may be that the same features predict treatment success across time. However, because these characteristics can change dynamically *within an individual*, what was the right treatment based on pre-quit characteristics is no longer the right treatment by 12 weeks, 6 months, or beyond. Many of the features used for prediction in this model were baseline measurements of *current* states - withdrawal, dependence, confidence/motivation to quit, time around other smokers, distress tolerance, depression symptoms, among others. Even features that feel more “static” like employment or marital status can be subject to change.

Dynamic change is the rule rather than the exception when it comes to chronic diseases like substance use disorders. Tobacco and other substance use disorders are dynamic and relapsing; both risk for use and the factors driving that risk fluctuate over time (Brandon et al., 2007). This change over time has been identified as a key barrier to overcome for precision mental health goals in addiction (Oliver & McClernon, 2017).

Accounting for dynamic changes will require ongoing assessment of key features that predict treatment success. Such monitoring is now feasible given developments in personal sensing (i.e., in situ data collection via sensors embedded in individuals’ daily lives) (Bae et al., 2018; Chih et al., 2014; Epstein et al., 2020; Soyster et al., 2022; Wyant et al., 2024) and is acceptable to individuals with substance use disorders (Wyant et al., 2023). Sensing via ecological momentary assessment is well-positioned to capture the self-report items used as features in this treatment selection model. Although frequently answering a 50-item survey is likely not feasible, it may be that more proximal features have greater predictive power, thus requiring fewer features for successful treatment selection. Indeed, in previous work in our laboratory, we have been able to predict hour-by-hour probabilities of alcohol lapses quite accurately (auROCs > 0.9) when using self-report features measured much closer to the outcome (Wyant et al., 2024).

Using this dynamic monitoring, we can select and adapt treatments and supports over time. There are certainly opportunities to adapt medications – for example, titrating doses or identifying moments when someone could benefit most from a lozenge. In general, medications are more static treatments that are less well-suited to dynamic changes, but they do not need to be used on their own. We observed that matching people to the right medication improves treatment success at 4 weeks. Medications could help create early treatment success that positions people to engage with additional supports that might be able to adapt more dynamically. Alternative treatments and supports via web-based interventions and mobile health apps may offer platforms for sustainable, scalable, ongoing support. We can recommend specific modules and individual tools that map onto currently important features affecting treatment success. This mapping between risk factors and supports is likely to be quite complex and will require considerable future research. But if we hope to advance precision mental health for smoking, addiction, and even mental health broadly, we must consider the dynamic nature of risk and recovery inherent in these conditions.

### **Interpreting our treatment selection model**

Several recent reviews have noted that the low interpretability of “black box” machine learning models may impede their utility for clinical and public health goals (Cohen & DeRubeis, 2018; MacEachern & Forkert, 2021; Mooney & Pejaver, 2018). Consequently, we aimed to make our model as interpretable as possible. We identified features that predict differential treatment success (i.e., features that interact with treatment to help us select among treatments). Our best selected model configuration retained 74 interaction terms that spanned 52 unique items. Each feature’s associated global Shapley value, which indicates overall magnitude of feature importance, was relatively small. This finding supports what has long been suspected in precision mental health: There is no one feature that explains sufficient variance to make differential predictions by treatment on its own. Rather, each feature offers only a small contribution, but many features together can guide treatment selection.

We also identified features that predict treatment success overall (i.e., “main effects”). These features contribute to the smoking cessation literature and support the conclusion from a recent review that predictors of treatment success span many categories (Bickel et al., 2023). We found similar breadth in important features in this model: economic (e.g., income), environmental (e.g., living with another smoker), sociodemographic (e.g., marital status), psychological (e.g., depression

diagnosis), physical health (e.g., pain interfering with daily activities), and smoking use/history (e.g., longest previous quit attempt) characteristics all contributed to predicting treatment success.

Additionally, these “main effect” features may yet help to advance precision mental health goals. These features may represent mechanisms underlying smoking cessation success and thus offer targeted areas for future treatment development. They also may be used to tailor existing treatments to increase success across individuals. Main effect features in our model may also interact with other treatments not included in this study. For example, bupropion is another first-line smoking cessation medication (Cahill et al., 2013). It may be that some features in this model do not differentiate among C-NRT, nicotine patch, or varenicline but would differentiate between one of these treatments and bupropion.

### ***The role of demographic features***

Several demographic features emerged as important: race, gender, income, and marital status. Ethnicity did not emerge as an important feature, and race-based features were specifically related to identifying as a Black or White individual. However, the limited representation of Hispanic, Latino/a, Asian, Multiracial, and Native American/Alaska Native individuals in this sample warrants caution in drawing conclusions about the predictive utility of ethnicity- and race-based features.

In some contexts, it would be problematic to use features that tap into constructs delineating marginalized identities such as race or socioeconomic status. For example, making decisions about who gets insurance (or doesn’t) and who gets released earlier from prison (or doesn’t) based on race is discriminatory (e.g., (Farayola et al., 2023)). However, in the precision mental health landscape, we are not deciding *who* gets treatment. Rather, we are deciding *which* treatment to give a specific patient. Thus, we can take advantage of experiential or symptomatological differences as a result of characteristics such as race, ethnicity, sex, income, or comorbid health conditions to improve treatment outcomes across vulnerable subpopulations.

### ***The risk of transparency***

When patients and clinicians can easily see non-intuitive features, they may be dissuaded from using or trusting this treatment selection model. For example, an interaction feature with the Anxiety Sensitivity Index-3 item “When my throat is tight, I worry I will choke to death” was retained. Because it seems to indicate a rather severe level of anxiety about physical conditions, perhaps it offered more predictive power than other correlated features and was thus retained by GLMNet. Regardless of the reason, the reality is that seeing questions like this on a treatment selection assessment may make patients or clinicians doubt the trustworthiness of the model.

### **Future directions**

We made a concerted effort in this project to evaluate how our treatment selection model would perform for new patients using cross-validation procedures. Regardless, the ultimate test of this model’s clinical benefit will be in a prospective trial. This trial will offer two tests. First, it will assess whether using this model is feasible and acceptable to patients and clinicians in clinical practice. Second, we can evaluate the benefit of our treatment selection model in an entirely new sample. Individuals who receive their model-predicted best treatment could be compared to any one of several possible comparison groups. Individuals in the comparison group could receive a random treatment assignment (mimicking clinical trials). Alternatively, they could receive clinician-assigned treatment to mirror traditional treatment selection (and best clinical practice). Another option is that we could compare to a simpler model. For example, there is evidence that treatment success is lower when people are re-treated with the same treatment (Fiore et al., 2008; Gonzales et al., 2014; Heckman et al., 2017; Tønnesen et al., 1993) and that treatment adherence is higher when

people choose their preferred treatment (Cropsey et al., 2017). Thus, treatments in the comparison group could be assigned based on patient preference and re-treatment status. Each comparison offers different advantages and disadvantages that should be considered thoughtfully when designing a prospective trial.

## Conclusion

Overall, this study has potential for immediate benefit to individuals looking to quit smoking. Our treatment selection model can improve the probability of abstinence during early recovery by a statistically significant and clinically meaningful margin. Moreover, it can do so with a relatively low-burden assessment that uses widely accessible features. This treatment selection model may serve as an initial tool embedded in a continuing care landscape where treatments are adapted dynamically over time. The ultimate test of our model will be in a prospective trial that assesses its feasibility, acceptability, and effectiveness in clinical practice. We are optimistic about the promise our model holds to improve the public health burden of cigarette smoking.

## Bibliography

Adjei, K., & Ali, A. A. (2022). CO110 Comparative Effectiveness of Sertraline, Fluoxetine Vs Escitalopram Among Adults with Depression in the United States. *Value in Health*, 25(7), S324-S325. <https://doi.org/10.1016/j.jval.2022.04.206>

American Psychiatric Association. (2013). *Diagnostic and Statistical Manual of Mental Disorders* (Fifth Edition). American Psychiatric Association. <https://doi.org/10.1176/appi.books.9780890425596>

Bae, S., Chung, T., Ferreira, D., Dey, A. K., & Suffoletto, B. (2018). Mobile Phone Sensors and Supervised Machine Learning to Identify Alcohol Use Events in Young Adults: Implications for Just-in-Time Adaptive Interventions. *Addictive Behaviors*, 83, 42–47. <https://doi.org/10.1016/j.addbeh.2017.11.039>

Baggett, T. P., Tobey Matthew L., & Rigotti Nancy A. (2013). Tobacco Use among Homeless People — Addressing the Neglected Addiction. *New England Journal of Medicine*, 369(3), 201–204. <https://doi.org/10.1056/NEJMp1301935>

Baker, T. B., & McCarthy, D. E. (2021). Smoking Treatment: A Report Card on Progress and Challenges. *Annual Review of Clinical Psychology*, 17(Volume17, 2021), 1–30. <https://doi.org/10.1146/annurev-clinpsy-081219-090343>

Baker, T. B., Piper, M. E., Stein, J. H., Smith, S. S., Bolt, D. M., Fraser, D. L., & Fiore, M. C. (2016). Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. *JAMA*, 315(4), 371–379. <https://doi.org/10.1001/jama.2015.19284>

Bates, D., Maechler, M., Bolker, B., Walker, S., Christensen, R. H. B., Singmann, H., Dai, B., & Grothendieck, G. (2015). *lme4: Linear Mixed-Effects Models Using 'Eigen' and S4*.

Bickel, W. K., Tomlinson, D. C., Craft, W. H., Ma, M., Dwyer, C. L., Yeh, Y.-H., Tegge, A. N., Freitas-Lemos, R., & Athamneh, L. N. (2023). Predictors of Smoking Cessation Outcomes Identified by Machine Learning: A Systematic Review. *Addiction Neuroscience*, 6, 100068. <https://doi.org/10.1016/j.addicn.2023.100068>

Bickman, L. (2020). Improving Mental Health Services: A 50-Year Journey from Randomized Experiments to Artificial Intelligence and Precision Mental Health. *Administration and Policy in Mental Health*, 1–49. <https://doi.org/10.1007/s10488-020-01065-8>

Bickman, L., Lyon, A. R., & Wolpert, M. (2016). Achieving Precision Mental Health through Effective Assessment, Monitoring, and Feedback Processes. *Administration and Policy in Mental Health and Mental Health Services Research*, 43(3), 271–276. <https://doi.org/10.1007/s10488-016-0718-5>

Biecek, P. (2018). DALEX: Explainers for Complex Predictive Models in R. *Journal of Machine Learning Research*, 19(84), 1–5.

Brandon, T. H., Vidrine, J. I., & Litvin, E. B. (2007). Relapse and Relapse Prevention. *Annual Review of Clinical Psychology*, 3(1), 257–284. <https://doi.org/10.1146/annurev.clinpsy.3.022806.091455>

Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016). Nicotine Receptor Partial Agonists for Smoking Cessation. *The Cochrane Database of Systematic Reviews*, 2016(5). <https://doi.org/10.1002/14651858.CD006103.pub7>

Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013). Pharmacological Interventions for Smoking Cessation: An Overview and Network Meta-Analysis. *The Cochrane Database of Systematic Reviews*, 5, CD9329. <https://doi.org/10.1002/14651858.CD009329.pub2>

Center for High Throughput Computing. (2006). *Center for High Throughput Computing*. Center for High Throughput Computing. <https://doi.org/10.21231/GNT1-HW21>

Chen, L.-S., Baker, T. B., Miller, J. P., Bray, M., Smock, N., Chen, J., Stoneking, F., Culverhouse, R. C., Saccone, N. L., Amos, C. I., Carney, R. M., Jorenby, D. E., & Bierut, L. J. (2020). Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial. *Clinical Pharmacology & Therapeutics*, 108(6), 1315–1325. <https://doi.org/10.1002/cpt.1971>

Chen, L.-S., Horton, A., & Bierut, L. (2018). Pathways to Precision Medicine in Smoking Cessation Treatments. *Neuroscience Letters*, 669, 83–92. <https://doi.org/10.1016/j.neulet.2016.05.033>

Chenoweth, M. J., Schnoll, R. A., Novalen, M., Hawk, L. W., George, T. P., Cinciripini, P. M., Lerman, C., & Tyndale, R. F. (2016). The Nicotine Metabolite Ratio Is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio. *Nicotine & Tobacco Research*, 18(4), 491–495. <https://doi.org/10.1093/ntr/ntv125>

Chih, M.-Y., Patton, T., McTavish, F. M., Isham, A. J., Judkins-Fisher, C. L., Atwood, A. K., & Gustafson, D. H. (2014). Predictive Modeling of Addiction Lapses in a Mobile Health Application. *Journal of Substance Abuse Treatment*, 46(1), 29–35. <https://doi.org/10.1016/j.jsat.2013.08.004>

Cohen, Z. D., & DeRubeis, R. J. (2018). Treatment Selection in Depression. *Annual Review of Clinical Psychology*, 14(1), 209–236. <https://doi.org/10.1146/annurev-clinpsy-050817-084746>

Collins, L. M. (2018). *Optimization of Behavioral, Biobehavioral, and Biomedical Interventions: The Multiphase Optimization Strategy (MOST)*. Springer International Publishing. <https://doi.org/10.1007/978-3-319-72206-1>

Cornelius, M. E. (2020). Tobacco Product Use Among Adults — United States, 2019. *MMWR. Morbidity and Mortality Weekly Report*, 69. <https://doi.org/10.15585/mmwr.mm6946a4>

Coughlin, L. N., Tegge, A. N., Sheffer, C. E., & Bickel, W. K. (2020). A Machine-Learning Approach to Predicting Smoking Cessation Treatment Outcomes. *Nicotine & Tobacco Research*, 22(3), 415–422. <https://doi.org/10.1093/ntr/nty259>

Crawford, J. R., & Henry, J. D. (2004). The Positive and Negative Affect Schedule (PANAS): Construct Validity, Measurement Properties and Normative Data in a Large Non-Clinical Sample. *British Journal of Clinical Psychology*, 43(3), 245–265. <https://doi.org/10.1348/0144665031752934>

Cropsey, K. L., Hendricks, P. S., Schiavon, S., Sellers, A., Froelich, M., Shelton, R. C., & Carpenter, M. J. (2017). A Pilot Trial of In Vivo NRT Sampling to Increase Medication Adherence in Community Corrections Smokers. *Addictive Behaviors*, 67, 92–99. <https://doi.org/10.1016/j.addbeh.2016.12.011>

Cropsey, K., Eldridge, G. D., & Ladner, T. (2004). Smoking among Female Prisoners: An Ignored Public Health Epidemic. *Addictive Behaviors*, 29(2), 425–431. <https://doi.org/10.1016/j.addbeh.2003.08.014>

DeRubeis, R. J. (2019). The History, Current Status, and Possible Future of Precision Mental Health. *Behaviour Research and Therapy*, 123, 103506. <https://doi.org/10.1016/j.brat.2019.103506>

Dwyer, D. B., Falkai, P., & Koutsouleris, N. (2018). Machine Learning Approaches for Clinical Psychology and Psychiatry. *Annual Review of Clinical Psychology*, 14(1), 91–118. <https://doi.org/10.1146/annurev-clinpsy-032816-045037>

Epstein, D. H., Tyburski, M., Kowalczyk, W. J., Burgess-Hull, A. J., Phillips, K. A., Curtis, B. L., & Preston, K. L. (2020). Prediction of Stress and Drug Craving Ninety Minutes in the Future with Passively Collected GPS Data. *Npj Digital Medicine*, 3(1), 26. <https://doi.org/10/ghqvvcw>

Etter, J.-F., Vera Cruz, G., & Khazaal, Y. (2023). Predicting Smoking Cessation, Reduction and Relapse Six Months after Using the Stop-Tabac App for Smartphones: A Machine Learning Analysis. *BMC Public Health*, 23(1), 1076. <https://doi.org/10.1186/s12889-023-15859-6>

Farayola, M. M., Tal, I., Connolly, R., Saber, T., & Bendechache, M. (2023). Ethics and Trustworthiness of AI for Predicting the Risk of Recidivism: A Systematic Literature Review. *Information*, 14(8), 426. <https://doi.org/10.3390/info14080426>

Feczko, E., & Fair, D. A. (2020). Methods and Challenges for Assessing Heterogeneity. *Biological Psychiatry*, 88(1), 9–17. <https://doi.org/10.1016/j.biopsych.2020.02.015>

Fiore, M. C., Jaen, C. R., Baker, T. B., Bailey, W. C., Benowitz, N. L., Curry, S. J., Dorfman, S. F., Froelicher, E. S., Goldstein, M. G., Heaton, C. G., Henderson, P. N., Heyman, R. B., Koh, H. K., Kottke, T. E., Lando, H. A., Mecklenburg, R. E., Mermelstein, R. J., Mullen, P. D., Orleans, C. T., ... Wewers, M. E. (2008). *A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update. A U.S. Public Health Service Report*. Rockville, MD: U.S. Department of Health and Human Services, U.S. Public Health Service.



Glatard, A., Dobrinas, M., Gholamrezaee, M., Lubomirov, R., Cornuz, J., Csajka, C., & Eap, C. B. (2017). Association of Nicotine Metabolism and Sex with Relapse Following Varenicline and Nicotine Replacement Therapy. *Experimental and Clinical Psychopharmacology*, 25(5), 353–362. <https://doi.org/10.1037/pha0000141>

Gonzales, D., Hajek, P., Pliamm, L., Nackaerts, K., Tseng, L.-J., McRae, T. D., & Treadow, J. (2014). Retreatment with Varenicline for Smoking Cessation in Smokers Who Have Previously Taken Varenicline: A Randomized, Placebo-Controlled Trial. *Clinical Pharmacology and Therapeutics*, 96(3), 390–396. <https://doi.org/10.1038/clpt.2014.124>

Harrison, A., Ramo, D., Hall, S. M., Estrada-Gonzalez, V., & Tolou-Shams, M. (2020). Cigarette Smoking, Mental Health, and Other Substance Use among Court-Involved Youth. *Substance Use & Misuse*, 55(4), 572–581. <https://doi.org/10.1080/10826084.2019.1691593>

Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerström Test for Nicotine Dependence: A Revision of the Fagerström Tolerance Questionnaire. *British Journal of Addiction*, 86(9), 1119–1127.

Heckman, B. W., Cummings, K. M., Kasza, K. A., Borland, R., Burris, J. L., Fong, G. T., McNeill, A., & Carpenter, M. J. (2017). Effectiveness of Switching Smoking-Cessation Medications Following Relapse. *American Journal of Preventive Medicine*, 53(2), e63–e70. <https://doi.org/10.1016/j.amepre.2017.01.038>

Insel, T. R. (2014). The NIMH Research Domain Criteria (RDoC) Project: Precision Medicine for Psychiatry. *American Journal of Psychiatry*, 171(4), 395–397. <https://doi.org/10.1176/appi.ajp.2014.14020138>

Issabakhsh, M., Sánchez-Romero, L. M., Le, T. T. T., Liber, A. C., Tan, J., Li, Y., Meza, R., Mendez, D., & Levy, D. T. (2023). Machine Learning Application for Predicting Smoking Cessation among US Adults: An Analysis of Waves 1-3 of the PATH Study. *Plos One*, 18(6), e286883. <https://doi.org/10.1371/journal.pone.0286883>

Jacobson, N. C., Kowatsch, T., & Marsch, L. A. (Eds.). (2022). *Digital Therapeutics for Mental Health and Addiction: The State of the Science and Vision for the Future* (1st edition). Academic Press.

Jamal, A., Homa, D. M., O'Connor, E., Babb, S. D., Caraballo, R. S., Singh, T., Hu, S. S., & King, B. A. (2015). Current Cigarette Smoking among Adults - United States, 2005-2014. *MMWR. Morbidity and Mortality Weekly Report*, 64(44), 1233–1240. <https://doi.org/10.15585/mmwr.mm6444a2>

James, G., Witten, D., Hastie, T., & Tibshirani, R. (2013). *An Introduction to Statistical Learning: With Applications in R* (7th ed.). Springer-Verlag. <https://doi.org/10.1007/978-1-4614-7138-7>

Jha Prabhat, Ramasundarahettige Chinthanie, Landsman Victoria, Rostron Brian, Thun Michael, Anderson Robert N., McAfee Tim, & Peto Richard. (2013). 21st-Century Hazards of Smoking and Benefits of Cessation in the United States. *New England Journal of Medicine*, 368(4), 341–350. <https://doi.org/10.1056/NEJMsa1211128>

Jonathan, P., Krzanowski, W. J., & McCarthy, W. V. (2000). On the Use of Cross-Validation to Assess Performance in Multivariate Prediction. *Statistics and Computing*, 10(3), 209–229. <https://doi.org/10.1023/A:1008987426876>

- Jordan, C. J., & Xi, Z.-X. (2018). Discovery and Development of Varenicline for Smoking Cessation. *Expert Opinion on Drug Discovery*, 13(7), 671–683. <https://doi.org/10.1080/17460441.2018.1458090>
- Karaca-Mandic, P., Norton, E. C., & Dowd, B. (2012). Interaction Terms in Nonlinear Models. *Health Services Research*, 47(1pt1), 255–274. <https://doi.org/10.1111/j.1475-6773.2011.01314.x>
- Kaufmann, A., Hitsman, B., Goelz, P. M., Veluz-Wilkins, A., Blazekovic, S., Powers, L., Leone, F. T., Gariti, P., Tyndale, R. F., & Schnoll, R. A. (2015). Rate of Nicotine Metabolism and Smoking Cessation Outcomes in a Community-based Sample of Treatment-Seeking Smokers. *Addictive Behaviors*, 51, 93–99. <https://doi.org/10.1016/j.addbeh.2015.07.019>
- Kaye, J. T., Johnson, A. L., Baker, T. B., Piper, M. E., & Cook, J. W. (2020). Searching for Personalized Medicine for Binge Drinking Smokers: Smoking Cessation Using Varenicline, Nicotine Patch, or Combination Nicotine Replacement Therapy. *Journal of Studies on Alcohol and Drugs*, 81(4), 426–435. <https://doi.org/10.15288/jsad.2020.81.426>
- Kelly, P. J., Baker, A. L., Deane, F. P., Kay-Lambkin, F. J., Bonevski, B., & Tregarthen, J. (2012). Prevalence of Smoking and Other Health Risk Factors in People Attending Residential Substance Abuse Treatment. *Drug and Alcohol Review*, 31(5), 638–644. <https://doi.org/10.1111/j.1465-3362.2012.00465.x>
- Kessler, R. C., & Luedtke, A. (2021). Pragmatic Precision Psychiatry—A New Direction for Optimizing Treatment Selection. *JAMA Psychiatry*, 78(12), 1384–1390. <https://doi.org/10.1001/jamapsychiatry.2021.2500>
- Kilaru, A. S., Xiong, A., Lowenstein, M., Meisel, Z. F., Perrone, J., Khatri, U., Mitra, N., & Delgado, M. K. (2020). Incidence of Treatment for Opioid Use Disorder Following Nonfatal Overdose in Commercially Insured Patients. *JAMA Network Open*, 3(5), e205852. <https://doi.org/10.1001/jamanetworkopen.2020.5852>
- Kiluk, B. D., Dreifuss, J. A., Weiss, R. D., Morgenstern, J., & Carroll, K. M. (2013). The Short Inventory of Problems – Revised (SIP-R): Psychometric Properties within a Large, Diverse Sample of Substance Use Disorder Treatment Seekers. *Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors*, 27(1), 307–314. <https://doi.org/10.1037/a0028445>
- Kranzler, H. R., Smith, R. V., Schnoll, R., Moustafa, A., & Greenstreet-Akman, E. (2017). Precision Medicine and Pharmacogenetics: What Does Oncology Have That Addiction Medicine Does Not?. *Addiction*, 112(12), 2086–2094. <https://doi.org/10.1111/add.13818>
- Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: Validity of a Brief Depression Severity Measure. *Journal of General Internal Medicine*, 16(9), 606–613. <https://doi.org/10.1046/j.1525-1497.2001.016009606.x>
- Krstajic, D., Buturovic, L. J., Leahy, D. E., & Thomas, S. (2014). Cross-Validation Pitfalls When Selecting and Assessing Regression and Classification Models. *Journal of Cheminformatics*, 6. <https://doi.org/10.1186/1758-2946-6-10>
- Kuhn, M. (2022). *Tidy posterior: Bayesian Analysis to Compare Models Using Resampling Statistics*.

Kuhn, M., & Johnson, K. (2018). *Applied Predictive Modeling* (1st ed. 2013, Corr. 2nd printing 2018 edition). Springer. <https://doi.org/10.1007/978-1-4614-6849-3>

Kuhn, M., & Wickham, H. (2020). *Tidymodels: A Collection of Packages for Modeling and Machine Learning Using Tidyverse Principles*.

Lai, C.-C., Huang, W.-H., Chang, B. C.-C., & Hwang, L.-C. (2021). Development of Machine Learning Models for Prediction of Smoking Cessation Outcome. *International Journal of Environmental Research and Public Health*, 18(5), 2584. <https://doi.org/10.3390/ijerph18052584>

Lenzner, T., Kaczmarek, L., & Lenzner, A. (2010). Cognitive Burden of Survey Questions and Response Times: A Psycholinguistic Experiment. *Applied Cognitive Psychology*, 24(7), 1003–1020. <https://doi.org/10.1002/acp.1602>

Lerman, C., Schnoll, R. A., Hawk, L. W., Cinciripini, P., George, T. P., Wileyto, E. P., Swan, G. E., Benowitz, N. L., Heitjan, D. F., Tyndale, R. F., & PGRN-PNAT Research Group. (2015). Use of the Nicotine Metabolite Ratio as a Genetically Informed Biomarker of Response to Nicotine Patch or Varenicline for Smoking Cessation: A Randomised, Double-Blind Placebo-Controlled Trial. *The Lancet. Respiratory Medicine*, 3(2), 131–138. [https://doi.org/10.1016/S2213-2600\(14\)70294-2](https://doi.org/10.1016/S2213-2600(14)70294-2)

Lewis, C., Roberts, N. P., Andrew, M., Starling, E., & Bisson, J. I. (2020). Psychological Therapies for Post-Traumatic Stress Disorder in Adults: Systematic Review and Meta-Analysis. *European Journal of Psychotraumatology*, 11(1), 1729633. <https://doi.org/10.1080/20008198.2020.1729633>

Lieberman, J. A. (2004). Dopamine Partial Agonists: A New Class of Antipsychotic. *CNS Drugs*, 18(4), 251–267. <https://doi.org/10.2165/00023210-200418040-00005>

Lindson, N., Chepkin, S. C., Ye, W., Fanshawe, T. R., Bullen, C., & Hartmann-Boyce, J. (2019). Different Doses, Durations and Modes of Delivery of Nicotine Replacement Therapy for Smoking Cessation. *Cochrane Database of Systematic Reviews*, 4. <https://doi.org/10.1002/14651858.CD013308>

Lundberg, S. M., & Lee, S.-I. (2017). A Unified Approach to Interpreting Model Predictions. *Proceedings of the 31st International Conference on Neural Information Processing Systems*, 4768–4777.

MacEachern, S. J., & Forkert, N. D. (2021). Machine Learning for Precision Medicine. *Genome*, 64(4), 416–425. <https://doi.org/10.1139/gen-2020-0131>

Mandrekar, J. N. (2010). Receiver Operating Characteristic Curve in Diagnostic Test Assessment. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*, 5(9), 1315–1316. <https://doi.org/10.1097/JTO.0b013e3181ec173d>

Marszalek, J. M., Barber, C., Kohlhart, J., & Cooper, B. H. (2011). Sample Size in Psychological Research over the Past 30 Years. *Perceptual and Motor Skills*, 112(2), 331–348. <https://doi.org/10.2466/03.11.PMS.112.2.331-348>

Massago, M., Massago, M., Iora, P. H., Tavares Gurgel, S. J., Conegero, C. I., Carolino, I. D. R., Mushi, M. M., Chaves Forato, G. A., de Souza, J. V. P., Hernandez Rocha, T. A., Bonfim, S., Staton, C. A., Nihei, O. K., Vissoci, J. R. N., & de Andrade, L. (2024). Applicability

of Machine Learning Algorithm to Predict the Therapeutic Intervention Success in Brazilian Smokers. *Plos One*, 19(3), e295970. <https://doi.org/10.1371/journal.pone.0295970>

Mooney, S. J., & Pejaver, V. (2018). Big Data in Public Health: Terminology, Machine Learning, and Privacy. *Annual Review of Public Health*, 39, 95–112. <https://doi.org/10.1146/annurev-publhealth-040617-014208>

Moriarty, D. (1996). CDC Studies Community Quality of Life. *NACCHO News*, 10, 13.

National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. (2014). *The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General*. Centers for Disease Control and Prevention (US).

Netzer, N. C., Stoohs, R. A., Netzer, C. M., Clark, K., & Strohl, K. P. (1999). Using the Berlin Questionnaire to Identify Patients at Risk for the Sleep Apnea Syndrome. *Annals of Internal Medicine*, 131(7), 485–491. <https://doi.org/10.7326/0003-4819-131-7-199910050-00002>

Ng, A. (2018). *Machine Learning Yearning*. 1–118.

Olfson, M., Mauro, C., Wall, M. M., Choi, C. J., Barry, C. L., & Mojtabai, R. (2022). Healthcare Coverage and Service Access for Low-Income Adults with Substance Use Disorders. *Journal of Substance Abuse Treatment*, 137, 108710. <https://doi.org/10.1016/j.jsat.2021.108710>

Oliver, J. A., & McClernon, F. J. (2017). Precision Medicine in Addiction Research: Where Has the Time Gone?. *Addiction*, 112(12), 2096–2097. <https://doi.org/10.1111/add.14023>

Pinedo, M. (2019). A Current Re-Examination of Racial/Ethnic Disparities in the Use of Substance Abuse Treatment: Do Disparities Persist?. *Drug and Alcohol Dependence*, 202, 162–167. <https://doi.org/10.1016/j.drugalcdep.2019.05.017>

Piper, Megan E., Cook, et al. (2017). Toward Precision Smoking Cessation Treatment II: Proximal Effects of Smoking Cessation Intervention Components on Putative Mechanisms of Action. *Drug and Alcohol Dependence*, 171, 50–58. <https://doi.org/10.1016/j.drugalcdep.2016.11.027>

Piper, M. E., Fiore, M. C., Smith, S. S., Fraser, D., Bolt, D. M., Collins, L. M., Mermelstein, R., Schlam, T. R., Cook, J. W., Jorenby, D. E., Loh, W.-Y., & Baker, T. B. (2016). Identifying Effective Intervention Components for Smoking Cessation: A Factorial Screening Experiment. *Addiction (Abingdon, England)*, 111(1), 129–141. <https://doi.org/10.1111/add.13162>

Piper, Megan E., Schlam, et al. (2017). Toward Precision Smoking Cessation Treatment I: Moderator Results from a Factorial Experiment. *Drug and Alcohol Dependence*, 171, 59–65. <https://doi.org/10.1016/j.drugalcdep.2016.11.025>

Rigotti, N. A., Kruse, G. R., Livingstone-Banks, J., & Hartmann-Boyce, J. (2022). Treatment of Tobacco Smoking: A Review. *JAMA*, 327(6), 566–577. <https://doi.org/10.1001/jama.2022.0395>

Schlam, T. R., & Baker, T. B. (2013). Interventions for Tobacco Smoking. *Annual Review of Clinical Psychology*, 9, 675–702. <https://doi.org/10.1146/annurev-clinpsy-050212-185602>

Schnoll, R. A., Patterson, F., Wileyto, E. P., Tyndale, R. F., Benowitz, N., & Lerman, C. (2009). Nicotine Metabolic Rate Predicts Successful Smoking Cessation with Transdermal Nicotine: A Validation Study. *Pharmacology Biochemistry and Behavior*, 92(1), 6–11. <https://doi.org/10.1016/j.pbb.2008.10.016>

Shahab, L., Bauld, L., McNeill, A., & Tyndale, R. F. (2019). Does the Nicotine Metabolite Ratio Moderate Smoking Cessation Treatment Outcomes in Real-World Settings? A Prospective Study. *Addiction*, *114*(2), 304–314. <https://doi.org/10.1111/add.14450>

Siegel, S. D., Lerman, C., Flitter, A., & Schnoll, R. A. (2020). The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions. *Cancer Prevention Research*, *13*(3), 261–272. <https://doi.org/10.1158/1940-6207.CAPR-19-0259>

Simons, J. S., & Gaher, R. M. (2005). The Distress Tolerance Scale: Development and Validation of a Self-Report Measure. *Motivation and Emotion*, *29*(2), 83–102. <https://doi.org/10.1007/s11031-005-7955-3>

Smets, E. M. A., Garssen, B., Bonke, B., & De Haes, J. C. J. M. (1995). The Multidimensional Fatigue Inventory (MFI) Psychometric Qualities of an Instrument to Assess Fatigue. *Journal of Psychosomatic Research*, *39*(3), 315–325. [https://doi.org/10.1016/0022-3999\(94\)00125-O](https://doi.org/10.1016/0022-3999(94)00125-O)

Smith, S. S., Piper, M. E., Bolt, D. M., Fiore, M. C., Wetter, D. W., Cinciripini, P. M., & Baker, T. B. (2010). Development of the Brief Wisconsin Inventory of Smoking Dependence Motives. *Nicotine & Tobacco Research*, *12*(5), 489–499. <https://doi.org/10.1093/ntr/ntq032>

Smith, S. S., Piper, M. E., Bolt, D. M., Kaye, J. T., Fiore, M. C., & Baker, T. B. (2021). Revision of the Wisconsin Smoking Withdrawal Scale: Development of Brief and Long Forms. *Psychological Assessment*, *33*(3), 255–266. <https://doi.org/10.1037/pas0000978>

Snaith, R. P., Hamilton, M., Morley, S., Humayan, A., Hargreaves, D., & Trigwell, P. (1995). A Scale for the Assessment of Hedonic Tone the Snaith-Hamilton Pleasure Scale. *The British Journal of Psychiatry: The Journal of Mental Science*, *167*(1), 99–103. <https://doi.org/10.1192/bjp.167.1.99>

Soar, K., Dawkins, L., Robson, D., & Cox, S. (2020). Smoking amongst Adults Experiencing Homelessness: A Systematic Review of Prevalence Rates, Interventions and the Barriers and Facilitators to Quitting and Staying Quit. *Journal of Smoking Cessation*, *15*(2), 94–108. <https://doi.org/10.1017/jsc.2020.11>

Soyster, P. D., Ashlock, L., & Fisher, A. J. (2022). Pooled and Person-Specific Machine Learning Models for Predicting Future Alcohol Consumption, Craving, and Wanting to Drink: A Demonstration of Parallel Utility. *Psychology of Addictive Behaviors: Journal of the Society of Psychologists in Addictive Behaviors*, *36*(3), 296–306. <https://doi.org/10.1037/adb0000666>

Substance Abuse and Mental Health Services Administration. (2023). *Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health*.

Taylor, S., Zvolensky, M. J., Cox, B. J., Deacon, B., Heimberg, R. G., Ledley, D. R., Abramowitz, J. S., Holaway, R. M., Sandin, B., Stewart, S. H., Coles, M., Eng, W., Daly, E. S., Arrindell, W. A., Bouvard, M., & Cardenas, S. J. (2007). Robust Dimensions of Anxiety Sensitivity: Development and Initial Validation of the Anxiety Sensitivity Index-3. *Psychological Assessment*, *19*(2), 176–188. <https://doi.org/10.1037/1040-3590.19.2.176>

Taylor, V. R., & National Center for Chronic Disease Prevention and Health Promotion (U.S.). Division of Adult and Community Health. (2000). *Measuring Healthy Days: Population Assessment of Health-Related Quality of Life*.

Tønnesen, P., Nørregaard, J., Säwe, U., & Simonsen, K. (1993). Recycling with Nicotine Patches in Smoking Cessation. *Addiction (Abingdon, England)*, 88(4), 533–539. <https://doi.org/10.1111/j.1360-0443.1993.tb02060.x>

Wang, J., Simons-Morton, B. G., Farhat, T., Farhart, T., & Luk, J. W. (2009). Socio-Demographic Variability in Adolescent Substance Use: Mediation by Parents and Peers. *Prevention Science: The Official Journal of the Society for Prevention Research*, 10(4), 387–396. <https://doi.org/10.1007/s11121-009-0141-1>

Weisz, J. R., Kuppens, S., Ng, M. Y., Vaughn-Coaxum, R. A., Ugueto, A. M., Eckshtain, D., & Corteselli, K. A. (2019). Are Psychotherapies for Young People Growing Stronger? Tracking Trends Over Time for Youth Anxiety, Depression, Attention-Deficit/Hyperactivity Disorder, and Conduct Problems. *Perspectives on Psychological Science: A Journal of the Association for Psychological Science*, 14(2), 216–237. <https://doi.org/10.1177/1745691618805436>

Wyant, K., Moshontz, H., Ward, S. B., Fronk, G. E., & Curtin, J. J. (2023). Acceptability of Personal Sensing Among People With Alcohol Use Disorder: Observational Study. *JMIR Mhealth and Uhealth*, 11(1), e41833. <https://doi.org/10.2196/41833>

Wyant, K., Sant'Ana, S. J. K., Fronk, G., & Curtin, J. J. (2024). Machine Learning Models for Temporally Precise Lapse Prediction in Alcohol Use Disorder. *Psychopathology and Clinical Science*. <https://doi.org/10.31234/osf.io/cgsf7>

Youngstrom, E. A. (2014). A Primer on Receiver Operating Characteristic Analysis and Diagnostic Efficiency Statistics for Pediatric Psychology: We Are Ready to ROC. *Journal of Pediatric Psychology*, 39(2), 204–221. <https://doi.org/10.1093/jpepsy/jst062>

Zheng, Y., Wiebe, R. P., Cleveland, H. H., Molenaar, P. C. M., & Harris, K. S. (2013). An Idiographic Examination of Day-to-Day Patterns of Substance Use Craving, Negative Affect, and Tobacco Use Among Young Adults in Recovery. *Multivariate Behavioral Research*, 48(2), 241–266. <https://doi.org/10.1080/00273171.2013.763012>